ArticleScientific reports2025
Treatment outcomes and predictors of success for multidrug resistant tuberculosis MDR TB in Ugandan regional referral hospitals.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Drivers of drug-resistant tuberculosis treatment initiation delay at three tertiary health facilities in Uganda: A mixed-methods study.Journal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- Bridging the Gap Between Treatment and Accountability: DR-TB Outcomes and Governance Signals in Rural Eastern Cape, South Africa (2020-2024).Infectious disease reports · 2026Article
- Shifts in tuberculosis treatment outcomes despite timely treatment initiation during and after the COVID-19 pandemic: a retrospective cohort study in a tertiary-level hospital in Mexico.BMC infectious diseases · 2026Article
- Predictors of Treatment Outcomes Among HIV-Positive Patients with Drug-Resistant Tuberculosis in Rural Eastern Cape, South Africa: A Retrospective Cohort Study.International journal of environmental research and public health · 2026Article
- Drug Resistance and Risk Factors of Bacteriologically Confirmed Tuberculosis Cases in 10 Sites - Hunan Province, China, 2018-2025.China CDC weekly · 2026Article
- Spatial Epidemiological Approach to Tuberculosis Treatment Outcomes in a Tertiary-Level Hospital: A Retrospective Analysis.Tropical medicine and infectious disease · 2026Article
- Tuberculosis notification trends and treatment outcomes in Bangladesh: findings from a National TB Program data, 2019-2021.BMC infectious diseases · 2026Article
- Success rates of DR-TB patients and associated factors in Tanzania: a six-year cohort study.BMC infectious diseases · 2026Article
- Tuberculosis: An Ongoing Global Threat.Advances in experimental medicine and biology · 2026Review
- Common Adverse Reactions and Management Strategies of First-Line Anti-Tuberculosis Drugs.Infection and drug resistance · 2026Review
- Strengthening Clinical Governance and Public Health Interventions to Improve Drug-Resistant Tuberculosis Outcomes in Rural South Africa.Healthcare (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug-resistant tuberculosis (MDR-TB) is a form of tuberculosis caused by strains resistant to both isoniazid and rifampicin, the most critical first-line drugs. Managing MDR-TB presents substantial challenges due to prolonged and costly treatment regimens, which are less effective than those for drug-susceptible TB. These difficulties are further exacerbated in low-resource settings by inadequate healthcare infrastructure, limited diagnostic capacity, and suboptimal access to treatment. Uganda, a high-burden TB country, faces persistent challenges in meeting national MDR-TB treatment targets, with high mortality rates and unfavourable outcomes. This study evaluated the treatment outcomes and factors associated with success among MDR-TB patients in regional referral hospitals. Of the 293 registered patients, 284 were included in the analysis, with a median age of 38 years (IQR: 30-45) and a predominance of male patients (65.1%). Overall, 68.7% of patients achieved successful treatment outcomes, while 31.3% experienced unfavourable outcomes. Multivariate analysis identified weight at treatment initiation (41-49 kg) as significantly associated with poor outcomes. These findings highlight a treatment success rate below national targets, with persistent high mortality and treatment failure in several regions. Addressing these challenges requires the development of innovative therapies and personalized care strategies to improve MDR-TB management in Uganda.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.